CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference
29. Oktober 2020 11:15 ET
|
Vaccinex, Inc.
SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease Data provide strong rationale for continued development in...
Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference
29. Oktober 2020 07:55 ET
|
Vaccinex, Inc.
SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease Data provide strong rationale for continued development...
Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab
22. September 2020 07:30 ET
|
Vaccinex, Inc.
Key cognitive endpoints trending towards but did not reach statistical significance in early manifest population. Overall study does not meet pre-specified co-primary endpoints Results support...
Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
17. September 2020 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a novel approach to treating cancer and neurodegenerative disease...
Vaccinex Announces Appointment of Robert Scala as Chief Commercial Officer
27. August 2020 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease...
Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s Disease
07. Juli 2020 07:55 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., July 07, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease...
Vaccinex Announces up to $16.5 Million in Equity Financing Agreements and Provides an Update on COVID-19 Impact on its Clinical Programs
31. März 2020 07:55 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 31, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth International Cancer lmmunotherapy Conference in Paris, France
27. September 2019 06:05 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex Reports Second Quarter 2019 Financial Results and Provides Corporate Update
14. August 2019 08:30 ET
|
Vaccinex, Inc.
Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected in the second half of 2019 Presented interim data...
Vaccinex Announces Full Enrollment Achieved in Ongoing CLASSICAL-Lung Phase 1b/2 Trial of Pepinemab in Combination with BAVENCIO® (avelumab) in Advanced Non-Small Cell Lung Cancer
13. August 2019 08:05 ET
|
Vaccinex, Inc.
63% of evaluable subjects whose tumors had progressed during prior checkpoint inhibitor therapy benefited from treatment with the combination of pepinemab and avelumab Primary completion anticipated...